Aarti Pharmalabs Past Earnings Performance
Past criteria checks 3/6
Aarti Pharmalabs has been growing earnings at an average annual rate of 32.2%, while the Pharmaceuticals industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 6.1% per year. Aarti Pharmalabs's return on equity is 12.3%, and it has net margins of 11.6%.
Key information
32.2%
Earnings growth rate
36.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 6.1% |
| Return on equity | 12.3% |
| Net Margin | 11.6% |
| Next Earnings Update | 05 Feb 2025 |
Recent past performance updates
Recent updates
Does Aarti Pharmalabs (NSE:AARTIPHARM) Deserve A Spot On Your Watchlist?
Oct 23
Should You Be Adding Aarti Pharmalabs (NSE:AARTIPHARM) To Your Watchlist Today?
May 31Estimating The Intrinsic Value Of Aarti Pharmalabs Limited (NSE:AARTIPHARM)
Apr 19These 4 Measures Indicate That Aarti Pharmalabs (NSE:AARTIPHARM) Is Using Debt Reasonably Well
Mar 21Revenue & Expenses Breakdown
How Aarti Pharmalabs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 19,680 | 2,281 | 1,569 | 0 |
| 30 Jun 24 | 19,497 | 2,253 | 1,508 | 0 |
| 31 Mar 24 | 18,526 | 2,169 | 1,448 | 0 |
| 31 Dec 23 | 18,319 | 1,945 | 1,394 | 0 |
| 30 Sep 23 | 18,548 | 1,895 | 1,380 | 0 |
| 30 Jun 23 | 19,462 | 1,887 | 1,325 | 0 |
| 31 Mar 23 | 19,452 | 1,935 | 1,349 | 0 |
| 31 Dec 22 | 20,601 | 2,118 | 1,391 | 0 |
| 30 Sep 22 | 21,885 | 2,252 | 1,469 | 0 |
| 30 Jun 22 | 16,573 | 1,741 | 1,156 | 0 |
| 31 Mar 22 | 11,999 | 1,223 | 852 | 0 |
| 31 Mar 21 | 0 | 0 | 0 | 0 |
Quality Earnings: AARTIPHARM has high quality earnings.
Growing Profit Margin: AARTIPHARM's current net profit margins (11.6%) are higher than last year (10.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AARTIPHARM's earnings have grown significantly by 32.2% per year over the past 5 years.
Accelerating Growth: AARTIPHARM's earnings growth over the past year (20.4%) is below its 5-year average (32.2% per year).
Earnings vs Industry: AARTIPHARM earnings growth over the past year (20.4%) did not outperform the Pharmaceuticals industry 21.2%.
Return on Equity
High ROE: AARTIPHARM's Return on Equity (12.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 09:26 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aarti Pharmalabs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|